Mirum Pharmaceuticals (MIRM) Enterprise Value (2018 - 2026)

Mirum Pharmaceuticals' Enterprise Value history runs 9 years deep, the most recent figure standing at -$386.3 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 39.11% year-over-year to -$386.3 million in Q1 2026; TTM through Mar 2026 was -$386.3 million, a 39.11% decrease from a year earlier, with the FY2025 full-year figure at -$383.3 million, down 36.54% from the prior year.
• Enterprise Value retreated to -$386.3 million in Q1 2026 per MIRM's latest filing, from -$383.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$94.0 million in Q3 2025 and bottomed at -$434.9 million in Q3 2022.
• The 5-year median for Enterprise Value is -$286.3 million (2023), against an average of -$280.5 million.
• Across the five-year window, Enterprise Value plunged 129.3% in 2024 and surged 66.95% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$251.7 million in 2022, then retreated by 13.75% to -$286.3 million in 2023, then increased by 1.95% to -$280.7 million in 2024, then slumped by 36.54% to -$383.3 million in 2025, then slipped by 0.76% to -$386.3 million in 2026.
• Per Business Quant, the three latest MIRM Enterprise Value figures stand at -$386.3 million (Q1 2026), -$383.3 million (Q4 2025), and -$94.0 million (Q3 2025).